

IVF in the Medically Complicated Patient

Second Edition

A Guide to
Management

Edited by
Nick S Macklon



Macklon IVF in the Medically Complicated Patient

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2014 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed on acid-free paper
Version Date: 20140304

International Standard Book Number-13: 978-1-4822-0669-2 (Paperback)

This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not necessarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional's own judgement, their knowledge of the patient's medical history, relevant manufacturer's instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the drug companies' printed instructions, and their websites, before administering any of the drugs recommended in this book. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as to advise and treat patients appropriately. The authors and publishers have also attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, micro-filming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Library of Congress Cataloging-in-Publication Data

IVF in the medically complicated patient : a guide to management / editor, Nick S. Macklon. -- Second edition.
p. ; cm. -- (Reproductive medicine and assisted reproductive techniques series)
In vitro fertilization in the medically complicated patient
Includes bibliographical references and index.
ISBN 978-1-4822-0669-2 (pbk. : alk. paper)
I. Macklon, Nick S., editor. II. Title: In vitro fertilization in the medically complicated patient. III. Series: Reproductive medicine & assisted reproductive techniques series.
[DNLN: 1. Fertilization in Vitro--contraindications. 2. Infertility--complications. WQ 208]

RG135
618.1780599--dc23

2014007812

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

Contents

Contributors	vii
1. The Patient with Cystic Fibrosis	1
<i>GCML Page-Christiaens, AJ Goverde, and F Teding van Berkhout</i>	
2. The Patient at Risk from Thrombosis	21
<i>NS Macklon</i>	
3. The Patient with Hyperprolactinaemia	31
<i>AN Andersen, MP Lauritsen, and M Krog</i>	
4. The Patient with Autoimmune Disease	39
<i>D Galliano, A Pellicer, and J Bellver</i>	
5. The Patient with Epilepsy	47
<i>E Campbell and J Craig</i>	
6. The Patient with Inflammatory Bowel Disease	59
<i>SV Kane and JG Al Hashash</i>	
7. The Patient with Hypertension	69
<i>BB van Rijn and MA Coleman</i>	
8. The Patient with Obesity	79
<i>T Hardy and W Ledger</i>	
9. The Patient with Polycystic Ovary Syndrome	91
<i>SMC De Sousa and RJ Norman</i>	
10. The Patient with Hydrosalpinx	103
<i>A Strandell</i>	
11. The Patient with Endometriosis	119
<i>Y Cheong</i>	

D Galliano, A Pellicer, and J Bellver

CONTENTS

Background	39
Systemic Lupus Erythematosus	39
Antiphospholipid Syndrome	40
Impact of SLE and APS on IVF and Pregnancy	41
Impact of IVF and Pregnancy on SLE and APS	42
Preparing the Patient for IVF	42
Management during IVF Treatment	43
Management in Early Pregnancy	44
References	44

KEY WORDS: *systemic lupus erythematosus, antiphospholipid syndrome, ovarian stimulation, infertility, IVF, pregnancy*

Background

Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease characterized by the production of autoantibodies and the presence of clinical manifestations affecting multiple organs.¹ SLE is a chronic disorder with an unpredictable course, alternating between periods of flares with remissions. The prevalence ranges from 20 to 150 cases per 100,000 persons and appears to be increasing due to better diagnosis and survival. The disease occurs nine times more often in women than in men, especially in women of childbearing age, and tends to be more severe among the black population. Due to earlier diagnosis and advances in treatments, the current life expectancy of such patients has improved to approximately 80% at 15 years. Even with these advances, however, one-third of SLE-related deaths in the United States occur in patients younger than 45 years due to active disease, cardiovascular complications, or infections secondary to immunosuppressive treatment.

SLE etiology is not fully known, but a strong genetic component has been shown

TABLE 4.1

Classification Clinical and Laboratory Criteria for SLE

-
1. Malar rash
 2. Discoid rash
 3. Photosensitivity
 4. Oral ulcers
 5. Arthritis
 6. Pleuritis or pericarditis
 7. Renal disorder
 8. Neurologic disorder
 9. Hematologic disorder
 10. Immunologic disorder
 11. Antinuclear antibodies
-

Source: Adapted from Bellver J, Pellicer A. *Fertil Steril* 2009 Dec;92(6):1803–10.

Note: Four of the 11 criteria are needed for the formal diagnosis.

Genes of the major histocompatibility complex (MHC), particularly HLA-A1, B8, and DR3, have been linked to SLE, as well as certain single-nucleotide polymorphisms (SNPs) that are associated with its clinical manifestations.²

Ninety percent of patients affected with SLE are women, and in genetically manipulated mice the presence of two X chromosomes increases the severity of the disorder, demonstrating the strong link between SLE and gender.² Environmental factors, such as smoking and exposure to ultraviolet radiation, have also been associated with SLE, as well as drugs such as procainamide, hydralazine and quinidine. Epstein–Barr virus (EBV) infection may also trigger lupus, as suggested by higher viral load in patients with SLE than in controls, as well as the inability of CD8+ T cells to control EBV-infected B cells. Genetic, epigenetic, environmental, and hormonal factors contribute to the expression of inflammation and damage to vital organs and tissues, especially joints, kidneys, skin, liver, and vessel walls, with varying degrees of severity, ranging from dermatologic and musculoskeletal symptoms to anemia, serositis, nephritis, and neuropsychiatric disorders.

Due to the clinical heterogeneity of the disease, 11 clinical or laboratory criteria have been established by the American College of Rheumatology, with a minimum of 4 criteria required for the correct diagnosis of SLE (95% specificity and 85% sensitivity) (Table 4.1).

Treatment of the disease includes nonsteroidal anti-inflammatory medications, antimalarial agents, glucocorticoids and immunosuppressive/cytotoxic drugs, such as hydroxychloroquine, azathioprine, methotrexate and cyclophosphamide.

respectively, with the risk of thrombosis ranging from 0.5–30%. Catastrophic APS is rare and presents high mortality due to multiorgan failure. Although several pathogenic mechanisms explaining how aPLs cause thrombosis have been proposed, the relationship between aPLs and the wide variety of clinical findings – ranging from normal pregnancies to thromboembolism or obstetric complications – remains unclear.⁴

The revised classification criteria for APS (2006) include specific autoantibodies as a needed component of the diagnosis. The persistence of more than 12 weeks of high titers of anti- β 2-glycoprotein I (ab2GPI), or immunoglobulin (Ig) M and/or IgG anticardiolipin antibodies (ACAs) or lupus anticoagulant (LAC), is required. A diagnosis of APS is made if at least one of these clinical criteria and one of the laboratory criteria are met. The clinical criteria include vascular thrombosis and pregnancy morbidity, defined as recurrent early miscarriage, fetal death, preterm delivery (< 34 weeks) caused by placental insufficiency or preeclampsia, and small size for gestational age (birth weight < 5th percentile). Even if aPLs are closely related to pregnancy complications, no consensus exists regarding which specific autoantibodies are more predictive of adverse obstetric outcome. Indeed, some retrospective studies have suggested that the simultaneous presence of LAC, ACAs, and ab2GPI is the best predictor of at-risk patients; SLE or recurrent pregnancy loss (RPL) have been suggested by other investigators to have predictive power; and a recent prospective, multicenter study has shown that LAC is the only component of triple positivity that is strictly predictive.⁵

Impact of SLE and APS on IVF and Pregnancy

Fertility seems to be normal in women with SLE, except in cases of severe disease and ovarian failure secondary to cyclophosphamide (CTX) therapy, which is reported in up to 70% of patients. In this regard, ovarian or oocyte cryopreservation before receiving alkylating agents employed in SLE should be recommended to preserve future fertility.

Even though some retrospective studies have in the past suggested a relationship between antiphospholipid antibodies, infertility and poor assisted reproductive technique (ART) outcome, more recent studies, including from our own group, have not detected a higher prevalence of lupus anticoagulant or ACAs in infertile women compared to fertile egg donors. Indeed, neither the routine screening in the infertile population nor the anticoagulant therapy in the presence of antiphospholipid antibodies appears justified since such antibodies do not seem to affect ART outcome.

Pregnancy represents a dangerous period in which the rates of obstetrical complications are high, particularly the unexplained death of normal fetuses and recurrent spontaneous abortions prior to the 10th week of gestation, and the premature birth

TABLE 4.2

Clinical Situations in which Ovarian Stimulation Should Be Discouraged in Women with SLE

Acute flare (and the following 6–12 months)
Pulmonary hypertension or arterial hypertension
Valvulopathy or heart disease
Previous thromboembolism
Severe renal disease
Antiphospholipid syndrome and anti-Ro/anti-La antibodies

Source: Adapted from Bellver J, Pellicer A. *Fertil Steril* 2009 Dec;92(6):1803–10.

less than 6–12 months, arterial and pulmonary hypertension, renal involvement, and antiphospholipid or anti-Ro/anti-La antibodies (Table 4.2).

Impact of IVF and Pregnancy on SLE and APS

Women with SLE and APS undergoing controlled ovarian hyperstimulation (COH) and IVF are at increased risk of hormone-associated flare and venous and arterial thromboembolism due to the hypercoagulable state induced by high serum estradiol (E2) concentrations, as well as enhanced risk of maternal and fetal complications. A planned and short COH with administration of prophylactic therapy, during a remission phase of the disease, especially with corticosteroids and anticoagulants, increases the safety of the procedure and reduces the risk of these complications. Pregnancy may aggravate SLE in several ways, for instance, by increasing the likelihood of a flare, which occurs in late pregnancy or puerperium in 46.6% of cases; deteriorating renal function, especially in patients with hypertension, heavy proteinuria, or high serum creatinine concentration; and increasing the risk of maternal thrombosis, especially in the puerperium and when antiphospholipid antibodies are present.

Preparing the Patient for IVF

IVF physicians should be aware of the relationship between immunologic alterations and reproductive outcomes and therefore recommend thrombophilia screening, immunologic tests and genetic study to patients in the presence of RPL, chemical pregnancy losses, or two or three failed IVF cycles. According to the first recent world survey, the most ordered immunologic tests for RPL and repeated implantation failures (RIF) are ACAs, LAC, thyroid peroxidase antibody, and antinuclear antibody, as opposed to the less-frequently investigated NK assay, human leukocyte antigen study, Th1/Th2 study or immunophenotype assay.⁶

Women with antiphospholipid antibodies and no history of thrombosis should be treated with heparin from the beginning of the luteal phase after embryo transfer, when the risk of thrombosis is increased, and not prior to ovum retrieval. In contrast, women with antiphospholipid antibodies who have a history of thrombosis should be switched from oral anticoagulant therapy to heparin from the beginning of the ovarian stimulation. In both cases, heparin should be stopped 12–24 hours prior to ovum retrieval to reduce bleeding complications, re-started 6–12 hours later, and then maintained until the day of the pregnancy test and continued in case of pregnancy. To avoid bleeding, low-dose aspirin should be considered and interrupted 5 to 7 days before oocyte retrieval. In women with only SLE and not APS, anticoagulation is not recommended, but corticosteroids and immunosuppressants should be employed to reduce lupus flares, especially when gonadotropins are given.⁸

Management in Early Pregnancy

Pregnancy in patients with SLE/APS leads to an increased risk of maternal and fetal complications which require close monitoring with the involvement of experienced specialists. Despite the advances made in the management of these pregnancies, however, adverse outcomes, including preeclampsia, pregnancy loss, intrauterine growth restriction (IUGR), and prematurity, still remain frequent as well as placental ischemia due to poor vascularization and impairment of early placenta.

In order to prevent or promptly recognize these complications in early pregnancy, clinical and laboratory biomarkers have been investigated, but the current evidence has shown LAC to be the strongest factor predicting adverse pregnancy outcomes, especially thrombosis, in these women.^{9,10} Therefore, because of this increased rate of complications, early pregnancy must be strictly followed up, with strong consideration of the fact that some immunosuppressants, such as cyclophosphamide, mycophenolate mofetil, methotrexate and leflunomide, are contraindicated in pregnancy and lactation due to their teratogenicity.

REFERENCES

1. Gurevitz SL, Snyder JA, Wessel EK, et al. Systemic lupus erythematosus: A review of the disease and treatment options. *Consult Pharm* 2013 Feb;28(2):110–21. doi:10.4140/TCP.n.2013.110.
2. Tsokos GC. Systemic lupus erythematosus. *N Engl J Med* 2011 Dec;365(22):2110–21. doi:10.1056/NEJMr1100359. PMID 22129255.
3. Giannakopoulos B, Krilis S. The pathogenesis of the antiphospholipid syndrome. *N Engl J Med* 2013 Mar 14;368:1033–44. doi:10.1056/NEJMr1112830.
4. Du VX, Kelchtermans H, de Groot PG, de Laat B. From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: Pathogenic mechanisms of the

6. Kwak-Kim J, Han AR, Gilman-Sachs A, Fishel S, Leong M, Shoham Z. Current trends of reproductive immunology practices in in vitro fertilization (IVF) – a first world survey using IVF-Worldwide.com. *Am J Reprod Immunol* 2013 Jan;69(1):12–20. doi:10.1111/j.1600-0897.2012.01183.x. Epub 2012 Aug 8.
7. Mecacci F, Pieralli A, Bianchi B, Paidas MJ. The impact of autoimmune disorders and adverse pregnancy outcome. *Semin Perinatol* 2007;31:223–6.
8. Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. *Fertil Steril* 2009 Dec;92(6):1803–10.
9. Ostensen M, Clowse M. Pathogenesis of pregnancy complications in systemic lupus erythematosus. *Curr Opin Rheumatol* 2013 Sep;25(5):591–6. doi:10.1097/BOR.0b013e328363ebf7.
10. Lockshin MD. Pregnancy and antiphospholipid syndrome. *Am J Reprod Immunol* 2013 Jun;69(6):585–7. doi:10.1111/aji.12071. Epub 2012 Dec 28.